



PCT/EP 03/12206



The Patent Office Concept House Cardiff Road Newport South Wales

NP10 800

PRIORITY DOCUMENT SUBMITTED OR TRANSMITTED IN

COMPLIANCE WITH

COMPLIANCE WITH

RULE 17.1(a) OR (b)

REC'D **2 4 NOV 2003**WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

BEST AVAILABLE COPY

An Executive Agency of the Department of Trade and Industry

Patents Form 1/77

Patents Act 1977 (Rule 16)

The 1 1 NOV 2002 TONDOM

The Patent Office

Cardiff Road Newport Gwent NP10 8QQ

applicant, or

See note (d))

c) any named applicant is a corporate body.

Request for grant of a patent
(See the notes on the back of this form. You can also get
an explanatory leaflet from the Patent Office to help you fill in this form)

1.	Your reference		J3696(C)/TC	111	NGV 2002
2.	Patent application number (The Patent Office will fill in this part)	0226270).7		2633-8 DÖ2898 90-0226270.7
3.	Full name, address and postcode of the ceach applicant (underline all surnames)	or of	UNILEVER PL UNILEVER HO LONDON, EC4	OUSE, BLACK	KFRIARS
	Patents ADP number (if you know it)	•	.504 269360 02—	1628	200
	If the applicant is a corporate body, give country/state of its incorporation	the	UNITED KING	ром	
4.	Title of the invention	·	METHOD OF I	PRODUCING	RETINYL ESTERS
5.	Name of your agent (if you have one)		ELLIOTT, Peter	r William	
	"Address for Service" in the United King to which all correspondence should be se (including the postcode)		PATENT DEPA COLWORTH B BEDFORD, MK	IOUSE, SHAF	
	Patents ADP number (if you know it)			16281	003,
6.	If you are declaring priority from one or a earlier patent applications, give the count and the date of filing of the or of each of earlier applications and (if you know it) the each application number	ry these	Country Priority ap (if you kno	plication number ow it)	Date of filing (day / month / year)
7.	If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	, , , , , , , , , , , , , , , , , , , ,	Number of earlier app	lication	Date of filing (day/month/year)
8.	Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an invento there is an inventor who is not named as an applicant or	•	YES		

Patents Form 1/77

tau	ents Form 1///			
۶.	Inter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document			
	Continuation sheets of this form			
	Description	20		
	Claim(s)	2		
	Abstract	1	O 4 +	
	Drawing(s)	3 +B	***/	
.0.	If you are also filing any of the following, state how may against each item.			_
	Priority Documents		•	•
	Translations of priority documents	•		
	Statement of inventorship and right to grant of a patent (Patents Form 7/77)	,		
	Request for preliminary examination and search (Patents Form 9/77)	1		
	Request for substantive examination (Patents Form 10/77)			
	Any other documents (please specify)			<u> </u>
1.		I/We request th	ne grant of a patent on t	the basis of this application.
	,	Signature(s)	0	Date: 11 November 2002
		Sandra Jar	e EDWARDS, Author	orised Signatory
2.	Name and daytime telephone number of person to contact in the United Kingdom	Trudi Clar	k, Tel 01234 22 2360	
ommu nece. ct 19 oplica	ing an application for a patent has been filed, the conication of the invention should be prohibited or rest assary to prohibit or restrict your invention in this way 77 stops you from applying for a patent abroad v ation has been filed at least 6 weeks beforehand in the prohibiting publication or communication has bee	stricted under Sec y. Furthermore, ij vithout first getti ı the United Kin;	tion 22 of the Patents fyou live in the United ing written permission gdom for a patent for	Act 1977. You will be informed if i Kingdom, Section 23 of the Patents from the Patent Office unless an the same invention and either no
otes 	If you need help to fill in this form or you have any Write your answers in capital letters using black in If there is not enough space for all the relevant de and write "see continuation sheet" in the relevant p If you have answered 'Yes' Patents Form 7/77 will Once you have filled in the form you must remember For details of the fee and ways to pay please contains.	ık or_you may typı tails on any part vart(s). Any conti need to be filed. er to sign and dat	e.themof this form, please con nuation sheet should b	ntinue on a separate sheet of paper

DUPLICATE"

J3696(C)FF

10

15

20

25

30

Method of Producing Retinyl Esters

This invention relates to a method of producing retinyl esters. In particular, it relates to a beneficial method of producing retinyl esters of fatty acids from natural sources, such as fats and oils of plant and animal origin, using enzyme catalysis. The invention may also provide novel retinyl esters and oil compositions containing retinyl esters, which may be useful adjuncts to cosmetic compositions.

Retinol (vitamin A) and retinyl esters have long been added to cosmetic compositions to provide topical benefits. Retinol may typically be produced on an industrial scale by a totally synthetic route using inter alia acetone. The synthesis may generate retinyl acetate. Retinyl palmitate is another commonly used retinyl ester, which may typically be produced by trans-esterification of retinyl acetate with methyl palmitate, with the reaction being chemically catalysed. Retinyl esters have traditionally been preferred to retinol in topical products since they are easier to formulate, are more stable, and they are less irritant than the alcohol form, with the ester typically being hydrolysed in use to the alcohol on the skin.

It is also known for retinyl esters to be produced using enzymes. For example, JP62248495 describes generally the production of retinyl esters from retinyl acetate and Omethoxypolyethylene glycol modified lipases to produce long chain acid esters. This application also describes the production of retinyl oleate by similarly modified enzymes

in a medium comprising benzene saturated with water. However, in this teaching, the reactions between the vitamin A and the long chain fatty acids occur in organic solvent systems, such as e.g. benzene. Also, as the modified lipase is solubilised in the reaction system, significant further processing is required to separate the desired retinyl ester product from the reaction mixture.

It is also known from the Australian Journal of Chemistry,

45 (4) 641-649(1992), O'Connor C.J; Petricevic S.F and

Stanley R.A., that C. rugosa can be used in the production

of retinyl palmitate from free alcohol and fatty acid in

aqueous ethanol or biphasic mixtures of paraffin and water.

Again, this process requires the use of organic solvents.

15

In addition, WO 99/32105 (DCV, Inc) describes the production of conjugated linoleic acid esters in the presence of a lipase, which esters can include retinyl esters. However the application does not state how the retinyl esters were obtained and the examples shown for other esters require the use of solvent and significant processing to isolate the final products.

It is also suggested in Journal of Molecular Catalysis B: Enzymatic, 8, 275-280 (2000) (Maugard T; Legoy M.D) that 25 retinyl esters may be produced by enzymatic routes. production of .retinyl paper describes the oleate and lactate for incorporation cosmetic products. Again the retinyl esters are prepared in solvents using enzymes such as Candida antarctica or 30 Rhizomucor miehei. However, again this document suggests that a solvent is necessary for the reaction to be carried

out, and does not discuss the nature or source of the acyl donor.

The present invention aims to provide a new method of preparing retinyl esters for use e.g. in topical cosmetic compositions, which esters may have various benefits associated with them over prior art teachings, including being simpler and cheaper to produce, without the requirement for organic solvents or significant down-stream processing. Surprisingly the products of the invention also show much enhanced stability and reduced irritancy on the skin.

Thus, according to a first aspect of the invention, there is provided a method of producing a retinyl ester compound comprising subjecting a composition comprising retinol or a retinyl ester and a fat or oil of animal, vegetable or algal origin to enzyme catalysed trans-esterification in solvent free conditions to produce a retinyl ester.

20

25

15

· 10

In a further aspect, there is provided a composition comprising a fat or oil of animal, vegetable or algal origin containing retinyl esters of fatty acids contained in the animal, vegetable or algal fat or oil. The retinyl esters are preferably formed by enzyme catalysed transesterification.

In yet a further aspect, there is provided a retinyl ester of a fatty acid prepared by the method described above.

30

According to yet a further aspect there is provided a topical composition for application to human skin containing

10

15

20

a retinyl ester or a composition containing a retinyl ester prepared as described above.


According to yet a further aspect there is provided a cosmetic method of treating human skin comprising applying thereto a topical composition as described above.

According to yet a further aspect of the invention, there are provided novel retinyl fatty acid esters, such as (but not necessarily limited to) retinyl C18:3 and C18:4 conjugated fatty acid esters.

The method may be used to provide compositions containing a fat or oil of animal, vegetable or algal origin, and which contain (or from which may be isolated) retinyl esters with. fatty acid portions which reflect the fatty acid composition of that animal, vegetable or algal fat or oil. For example, when produced in sunflower oil, the method produces sunflower fatty acid retinyl esters from catalysed trans-esterification of sunflower oil. resultant retinyl esters are predominantly the linoleic and oleic forms, reflecting the fatty acid composition of the sunflower oil.

25 The method can be extended to the use of any fat or oil of animal, vegetable or algal origin.

As a result, the method can be used to synthesise retinyl esters containing fatty acids having C_{12-22} chain lengths, 30 either saturated or unsaturated. The resulting retinyl esters and retinyl ester blends have been found to be relatively mild compared to e.g. retinyl acetate or retinyl



10

palmitate made by conventional routes. The method also provides a route to the manufacture of retinyl esters and ester blends from a relatively cheap starting material, retinyl acetate, which is cheaper to prepare than materials such as retinyl palmitate.

As an enzyme to be used for the trans-esterfication process, preferably a lipase enzyme is used. Lipase enzymes are well known for their ability to catalyse (trans) esterification reactions involving oils and fats. Any suitable source of lipase can be utilised, though industrially produced lipases are preferred on a cost basis. The lipase should preferably be immobilised on a suitable carrier.

15 The fat or oil of animal, vegetable or algal origin is in fact a composition which contains either a free fatty acid, or an ester of fatty acids which are of animal, vegetable or algal origin. Any such oil or fat, being of natural origin will typically contain a population of free fatty acids acids or esterified fatty acids, although one or more may predominate in this population. However the population of free fatty acids or esterified fatty acids will typically characterise the animal or vegetable source.

25 Preferably, a fat or oil of animal, vegetable or algal origin is chosen such that the fatty acid content of the oil or fat of the hydrolysed esters in the oil or fat is relatively enriched in skin benefit agents. Preferred skin benefit agents for the oil or fat to be relatively high in (i.e. contain more than about 0.1%, preferably 0.5%, more preferably more than about 1.0% of) include (C18:1-C22:6),

10

15

20

25

particularly petroselinic acid or conjugated 18:2, 18:3 and 18:4 acids.

The invention has a number of benefits and distinguishing features over the prior art.

Firstly, in the process of the invention, retinol is transesterified with free fatty acids or more likely preferably) fatty acid esters in the oil or fat of animal, vegetable or algal origin. As a result, fatty acid side chains which were previously present in the reaction mixture as a fatty acid side chain in an ester such as a fatty acid triglyceride are now present as part of a retinol ester. Since the retinol ester is hydrolysed on the skin, retinol and the fatty acid are released. If the fatty acid is also a known skin benefit agent such as e.g. outlined above, on hydrolysis the skin is treated to a "double dose" of skin benefit agents, namely the retinol and the fatty acid, as well as possibly receiving some extra skin benefit from the fat or oil of animal, vegetable or algal origin itself. Fatty acids found in oils or fats of animal, vegetable or algal origin, especially in the triglycerides found therein, may provide a relatively cheap source of such benefit As such, an oil or fat used according to the agents. invention may be selected for its fatty acid profile (either in the form of free fatty acids or triglycerides).

In addition, since the trans-esterification reaction is carried out directly in the fat or oil of animal or vegetable origin in solvent free conditions, which fat or oil may itself have skin beneficial properties, there is no need to conduct any subsequent clean up operation either to

remove solvents from the reaction mixture or to isolate or concentrate the retinyl ester. Instead, the fat or oil containing the retinyl ester may be either applied directly the skin, or dosed into a topical composition To this end though, it is highly application to the skin. preferred that the enzyme used in the trans-esterification be immobilised on a solid support in such a way that it can be readily removed from the reaction mixture after transesterification, for example by filtration. immobilisation techniques are well known in the art, and include for example immobilisation on microporous which have polypropylene beads been pre-treated surfactant, to which is added an enzyme solution and which is subsequently washed and dried.

15

10

5

The enzyme may be used in normal functional conditions for that enzyme, which typically include simple mixing of the enzyme in a container with the other reactants, at temperatures up to about 70°C.

20

25

30

As mentioned above the trans-esterification reaction is carried out in solvent free conditions. By this is meant that the composition contains less than about 10% solvent, preferably less than about 5% solvent, more preferably less than about 1% solvent, and preferably is totally solvent free.

Solvents which are excluded from the transesterification reaction include water (the only water present is preferably only that which is associated with the enzyme itself), as well as short chain (i.e C_{1-6}) solvents such as alkanes and

alcohols, ketones and any esters which may interfere with the desired trans-esterification reaction.

The tranesterification reaction should take place in a medium which has a significant liquid phase, e.g. is a liquid or a paste.

Many preferred fatty acids which are the subject of the trans-esterification reaction are liquid at room temperature; many also contain a degree of unsaturation.

Retinyl esters produced according to the invention which have a fatty acid profile based on the fatty acid content of the corresponding animal, vegetable or algal oil or fat have been found to have surprisingly good physical stability compared to other single species fatty acid esters, as well as be surprisingly mild.

The resultant transesterified esters reflect the fatty acid
chain length composition of the animal or vegetable oil used
in the method. Hence exemplary retinyl esters which may be
prepared according to the invention are prepared using the
following plant and animal oils, and may have enriched fatty
acid ester contents as outlined below:

25

10

C12:0 - coconut oil, palm kernal

C14:0 and C14:1 - kombo nut (Pycnanthus angolensis) oil

C16:0 - palm oil

C18:0 and C18:1 - cocoa butter

Oll:1 - high oleic sunflower oil, olive oil, coriander seed---

C18:1 and C18:2 - corn oil, sunflower oil, cotton seed oil

C18:2 - safflower oil, grape seed oil, wheatgerm oil

C18:3 - borage oil, evening primrose oil, linseed oil, pine nut oils, Manketti nut oiland pomegranate seed oil

C18:4 - Impatiens balsamina seed oil

5 C20:5 and C22:6 - fish oils, algal oils

C22:1 - crambe oil, mustard seed oil

Preferred retinyl esters include those prepared from the fatty acids of plant oils, especially kombo nut oil, coriander oil, sunflower oil, safflower oil, pomegranate oil, borage oil and pine nut oil, as well as retinyl esters of conjugated fatty acids, especially C18 conjugated fatty acids. Unless otherwise purified the retinol esters which are the subject of the invention will invariably comprise a range of fatty chain lengths and types which reflect the fatty acid content of the fat or oil of animal or vegetable origin, or more likely its triglyceride fatty acid content.

Preferred species of retinyl conjugated fatty acid esters which are believed to be novel in their own right include:

- retinyl ester of punicic acid (18:3, c9, t11, c13), which can be prepared from pomegranate seed oil
- 25 retinyl ester of calendic acid (18:3, t8, t10, c12), which can be prepared from Calendula officinalis (Marigold) seed oil.
- retinyl ester of eleostearic acid (18:3, c9, t11, t13),

 which can be prepared from Manketti nuts (Ricinodendron rautanenii or Ricinodendron heudelotti), but which can also be prepared from cherry kernal oils (Prunus Cerasus,

20

- P. avium, P. mahaleb), tung oil, Momordica dioica (Chinese bitter melon), Parinari montana and Parinarium excelsis.
- retinyl ester of parinaric acid (18:4, c9, t11, t13, c15),
 which is preferably sourced from Impatiens balsamina L,
 but may also be sourced from Parinari glaberrimum,
 Lithospermum euchromum, Sebastiana brasiliensis, I.
 Edgeworthii, I.Pallida & capensis and Parinarium laurinum.
- The enzyme used in the method according to the invention is preferably a lipase enzyme, more preferably a lipase immobilised on a solid support. Examples of suitable lipase enzymes include Candida rugosa lipase, Lipase D and Lipozyme IM. Methods of immobilisation of lipases (where required) are described, for example, in EP424130.

Topical compositions for application to the human skin preferably comprise 0.00001 to 5%, preferably 0.0001 to 1%, more preferably 0.01 to 0.5% of the retinyl esters prepared according to the invention.

The invention will now be prepared by way of example only with reference to the accompanying drawings, in which:

- 25 Figure 1 shows the stability of retinyl esters according to the invention compared to commercially available retinyl palmitate and retinyl linoleate.
- Figure 2 shows the comparative stability of esters

- Figure 3 shows the relative irritancy of retinyl ester formulations.

Example 1

5

25

30

Example 1 - Production of retinyl esters using sunflower oil Sunflower oil (7.5 g) and retinyl palmitate (2.5g) were mixed and water (0.03 g) and immobilised Lipase D (Rhizopus 10 oryzae (Amano) immobilised on Accurel® EP100 macroporous polypropylene (Acordis) 0.1 g) or Candida rugosa AY (Amano) on Accurel® EP100 (Acordis) (CR; 0.1g) added. The mixtures were placed in a shaking water bath at 55°C for 20 or 23 hours. The immobilised lipase was then removed by simple 15 filtration to directly yield the product, a solution of retinol esters in triglyceride oil. The composition of the retinyl esters was separated from the triglycerides by thin layer chromatography (0.5mm silica G plates, Analtech Ltd.) using toluene as eluting solvent and visualised by spraying 20 with 1% 2,7-dichlorofluorescein in ethanol. The ester band was scraped off and FAMEs were produced using 3ML sodium methoxide and 1 mL toluene at 80°C for 20 minutes followed by 5 minutes at 80°C with boron trifluoride (2mL volumes of reagent). The fatty acid content was then analysed by Fatty ester Gas Chromatography methyl (FAME-GC). conditions: Column - 30m / 0.53mm / 0.5um restek famewax, Helium carrier gas 15kpa, flame ionisation detection, 260°C PTV injection (Run: 3min @ 260°C, 80°C hold 1min, +20/min to 180°C, +2/min to 220°C, +1/min to 230°C, +4min hold at 230°C).

15

As shown in Table 1, the palmitic acid content of the retinyl ester was reduced from 98.5%, being replaced predominantly by linoleic and oleic acids. The palmitic acid was incorporated into the sunflower triglycerides Table 1 - Sunflower retinyl esters produced from retinyl palmitate

Sample	C14:0	C16:0	C18:0	Other	C18:1 (oleate)	C18:2 (linoleate)	C18 (tot)
Retinyl palmitate starting material	0.4	98.5	0.7	0.4		0	0.7
Retinyl ester product (CR - 23h)	0.2	44	5.1	0.4	16.9	33.4	55.4
Retinyl ester product (LD - 20h)	0.2	28.9	5.1	1.7	21.2	42.9	69.2

Example 2 - Production of sunflower oil retinyl esters from retinyl acetate

Sunflower oil (7.5 g) and retinyl acetate (3.75 or 2.5g) were mixed and water (0.03 g) and 1% immobilised Rhizomucor miehei lipase (Lipozyme IM Novo Nordisk) added. The mixture was placed in a shaking water bath at 55°C for 4 days. The immobilised lipase was then removed by simple filtration to directly yield the product, a solution of retinol esters in triglyceride oil. The levels of retinyl esters were determined by peak collection from HPLC, with the addition

²⁰ of C17 methyl ester ISTD according to the following conditions:

Column:

10cm Nucleosil 100A 3um silica with precolumn.

Elution solvents - Solvent A - hexane/toluene 1:1; Solvent B - toluene/ethyl acetate/formic acid 600/200/16; solvent C - toluene/ethyl acetate/isopropyl alcohol/formic acid 500/200/100/16.

Time (Mins)	Solvent ratios (A/B/C)
0	99/ 1/ 0
. 4.9	99/ 1/ 0
5	90/ 10/ 0
6	75/ 25/ 0
7	40/ 60/ 0
9	10/ 90/ 0
9.1	0/ 10/ 90
· 12	0/ 10/ 90
12.1	10/ 90/ 0
15.0	10/ 90/ 0
15.1	99/ 1/ 0
30.0	99/ 1/ 0

Flow rate:

1.4mL/min

Detection:

15

Evaporative light scattering detector

10 (40°C/10L/min nitrogen)

The retinyl ester levels produced are shown in Table 2. The retinyl esters collected from the HPLC were converted to FAMEs using 2ML sodium methoxide at 80°C for 20 minutes. FAME-GC was performed as described previously (Table 3).

Table 2: Retinyl ester levels

Description	% Long chain
	retinyl esters
2:1 SF:RA Lipase SP392(supported) 4	. 20.4

days	
3:1 SF:RA Lipase SP392(supported) 4	17.3
days	,

Table 3: Fatty acid profile of retinyl esters

Fatty acid chain	2:1 SF:RA	3:1 SF:RA
length		·
16:0	14.2	12.7
16:1	0.9	3.4
18:0	5.1	5.0
18:1	22.6	22.2
18:2	55.1	54.3
18:3	0	0.3
20:0	0.8	0.7
20:1	0.8	01
22:0	0.5	0.9
22:1	0	0.4

Example 3 - Retinyl Linoleate stability in Moisturising 5 Cream formulations

Retinyl Linoleate from National Starch Corp. and the retinyl ester product from example 1 were blended into moisturising cream formulations shown below in Formulations 1 and 2 at a level of 0.03 and 0.15% of the retinyl ester The creams were stored at 22°C, 30°C, 45°C and 50°C and samples taken at time 0, and twice more over 35 days as shown in Figs. 1 and 2.

10


Formulation 1

Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Ingredient Name	%	Supplier
Mater, Spring 1.00 Local, Poland Springs	Phase A		
Single	Water	to 100	Local
Disodium EDTA 0.05 WR.Grace Panthenol 0.10 Roche Mg Amino Acid Chelate 0.01 Maypro Zn Amino acid Chelate 0.01 Maypro Green Tea extract 0.10 Tri-K Grapeseed Extract 0.10 Brooks Phase B Ultrez 10 0.75 BF Goodrich TEA 99 % 2.00 Dow Parsol HS 2.00 Roche Water 10.00 Local Lanett 14 (Myristal 0.50 Cognis Alcohol) Arlacel 60 (Sorbitan 1.20 ICI Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche dibenzoyl) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Water, Spring	1.00	Local, Poland Springs
Panthenol 0.10 Roche	Glycerin	5.00	Dow .
Mg Amino Acid Chelate	Disodium EDTA	0.05	WR.Grace
En Amino acid Chelate 0.01 Maypro Green Tea extract 0.10 Tri-K Grapeseed Extract 0.10 Brooks Phase B Ultrez 10 0.75 BF Goodrich TEA 99 % 2.00 Dow Parsol HS 2.00 Roche Water 10.00 Local Lanett 14 (Myristal 0.50 Cognis Alcohol) Arlacel 60 (Sorbitan 1.20 ICI Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Panthenol	0.10	Roche
Creen Tea extract	Mg Amino Acid Chelate	0.01	Maypro
### Comparison of Comparison o	Zn Amino acid Chelate	0.01	Maypro
### Phase B Ultrez 10	Green Tea extract	0.10 .	Tri-K
Dilaurate Dila	Grapeseed Extract	0.10	Brooks
Dilaurate Dila			
TEA 99 % 2.00 Dow Parsol HS 2.00 Roche Water 10.00 Local Lanett 14 (Myristal 0.50 Cognis Alcohol) Arlacel 60 (Sorbitan 1.20 ICI Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Phase B		
Parsol HS 2.00 Roche Water 10.00 Local Lanett 14 (Myristal 0.50 Cognis Alcohol) Arlacel 60 (Sorbitan 1.20 ICI Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Ultrez 10	0.75	BF Goodrich
Water 10.00 Local Lanett 14 (Myristal 0.50 Cognis Alcohol) Arlacel 60 (Sorbitan 1.20 ICI Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	TEA 99 %	2.00	Dow
Lanett 14 (Myristal 0.50 Cognis Alcohol) Arlacel 60 (Sorbitan 1.20 ICI Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Parsol HS	2.00	Roche
Alcohol) Arlacel 60 (Sorbitan 1.20 ICI Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Water	10.00	Local
Arlacel 60 (Sorbitan 1.20 ICI Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Lanett 14 (Myristal	0.50	Cognis
Stearate) Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Alcohol)		· ·
Cetyl Alcohol 0.50 Hankel Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Arlacel 60 (Sorbitan	1.20	ICI
Emulsynt GDL (Glycerol 0.50 ISP Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Stearate)		
Dilaurate) Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Cetyl Alcohol	0.50	Hankel ·
Stearyl Alcohol 0.50 RTD Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Emulsynt GDL (Glycerol	0.50	ISP
Ryoto Sugar Ester 0.25 Ryoto Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Dilaurate)		
Myrj 59 (PEG-100 Stearate) 0.50 ICI Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Stearyl Alcohol	0.50	RTD
Pristerene 4911 (Stearic 0.25 Stephan Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Ryoto Sugar Ester	0.25	Ryoto
Acid) Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Myrj 59 (PEG-100 Stearate)	0.50	ICI ·
Parsol MCX (Octyl methoxy 4.322 Roche cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Pristerene 4911 (Stearic	0.25	Stephan
cinnimate) Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Acid)		·
Parsol 1789 (Butyl Methoxy 2.00 Roche dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	Parsol MCX (Octyl methoxy	4.322	Roche
dibenzoyl) Dermablock OS (Octyl 3.90 Alzo	cinnimate)	•	
Dermablock OS (Octyl 3.90 Alzo	Parsol 1789 (Butyl Methoxy	2.00	Roche
	dibenzoyl)		
Salicylate)	Dermablock OS (Octyl	3.90	Alzo
	Salicylate)		

Viatamin E Acetate	0.10	Roche
Retinyl linoleate-National	1.5	
Starch		·
Incromide LSM Linoleate	0.01	Croda
Cholesterol NF	0.10	Croda
BHT .	0.02	
Tocomix	0.003	
Permethyl 101A	4.50	Presperse
Phenonip	0.54	Clariant
Phase C		
Vitamin A Palmitate	0.01	Roche
Fragrance Q26913	0.20	Quest ·
TOTAL .	100.00	

Formulation 2:

Ingredient Name	96	Supplier
Water	to 100	Local
Water, Spring	1.00	Local, Poland Springs
Glycerin	5.00	Dow
Disodium EDTA	0.05	WR Grace
Panthenol	0.10	Roche
Mg Amino acid Chelate	0.010	Maypro ·
Zn Amino acid chelate	0.010	Maypro
Green Tea Extract	0.100	Tri-K
Grape seed extract	0.100	Brooks
		·
Phase B		
Ultrez 10	0.75	BF Goodrich
TEA 99 %	2.00	Dow
Parsol HS	2.00	Roche
.Water	10.00	Local
Lanett 14 (Myristal Alcohol)	0.50	Cognis
Arlacel 60 (Sorbitan Stearate)	1.20	ICI



Cetyl Alcohol	0.50	Hankel,
Emulsynt GDL (Glycerol Dilaurate)	0.50	ISP
Stearyl Alcohol	0.50	RTD
Ryoto Sugar Ester	0.25	Ryoto
Myrj 59 (PEG-100 Stearate)	0.50	ICI
Pristerene 4911 (Stearic Acid)	0.25	Stephan
Parsol MCX (Octyl methoxy Cinnimate)	4.577	Roche
Parsol 1789 (Butyl Methoxy dibenzoyl)	2.00	Roche
Dermablock OS (Octyl Salicylate)	3.12	Alzo
Retinyl linoleate (from example 1)	1.5	
Incromide LSM (Linoleamide MEA)	0.01	Croda
Cholesterol NF	0.10	Croda
BHT	0.02	
Tocomix	0.003	
Permethyl 101A	4.50	Presperse
Phenonip	0.54	Clariant
Phase C		
Fragrance Q26913	0.20	Quest
Vitamin A Palmitáte	0.01	Roche
TOTAL	100.00	·

The retinyl esters were extracted from the base cream 60/40 acetone/acetonitrile, stirred for 10 minutes, filtered and then injected These were then analysed by HPLC according to the conditions below.

Column: Intersil 5 micron, ODS-2 (C18) from

Phenominex

10 Detection: UV at 325 nm

Mobile phase: 35% Acetone / 65% Acetonitrile

Flow Rate: 1.0 mL/minute

Peak Elution:

Approx 10 minutes

Calib Curve:

Standards - 1.5 ppm to 18 ppm for

samples containing 0.03 to 0.15% RL.

Figures 1 and 2 show the stability results for the samples. The retinyl ester product from example 1 was more stable than the National Starch retinyl linoleate. For comparison retinyl palmitate is only as stable as retinyl linoleate (National starch).

10

15

20

Example 4 - Stability of retinyl esters in oils

The stability of retinyl linoleate (National starch) and retinyl esters (example 1) in the fluid oil phase alone of a moisturising cream formulation as evaluated. Two fluid oil formulations were prepared by incorporating the desired amounts of the ingredients like Parsol MCX, Dermablock OS, Permethyl 101A and Vitamin E acetate as found in Formulation 1. One was spiked with retinyl esters (example 1) and the other with retinyl linoleate from National Starch (NS) at the 0.75% level. These were analysed initially and after twenty eight days at 50°C (Table 4)

25 Table 4: Stability of retinyl esters in the oil phase

Retinyl esters	% recovery
Retinyl linoleate	72.6
(NS)	
Retinyl esters	85.0
(Example 1)	

The data demonstrates that retinyl esters from example 1 are more stable in oil blends than retinyl linoleate.

Example 5 - Irritancy of retinyl esters

5 male and 15 female subjects were selected for the study, the aim of which was to compare the irritation potential of a Moisturising Cream alone and in combination with retinyl linoleate from example 1 vis National Starch material. The concentration of retinyl linoleate added to the moisturising cream from the 2 sources contained equal molar quantities of the retinyl moiety in ester form. Test materials were compared to a selected control statistically in a pairwise comparison based on Friedman's Rank Sums (p < 0.10 is considered significant, p values 0.2 and 0.15 are provided for informational purposes only).

Protocol:

20

10

15

The upper outer aspect of the upper arm was exposed to the test materials once for a 24 hour period followed by up to three 18 hour exposures, using 25 mm Hill Top® Chambers fitted with 18 mm Webril® padding and held in place with Scanpor® tape. 0.2 ml of the test materials was applied to the Webril® padding 1 hour before application.

Dose Characterization/ Verification and Stability and Microbiology:

The level of Retinyl linoleate was within target for all Test materials containing this material. All Test materials were found to be microbiology acceptable.

5 As shown in figure 3, the retinyl linoleate from example 1 (RL EX1) is far less irritant than the retinyl linoleate from National starch (RL NS).

Claims

5

- 1. A method of producing a retinyl ester compound comprising subjecting a composition comprising retinol or a retinyl ester and a fat or oil of animal or vegetable origins to enzyme catalysed transesterification in solvent free conditions to produce a retinyl ester.
- 10 2. A method according to claim 1 wherein the fat or oil of animal or vegetable origin contains one or more C_{12-22} saturated or unsaturated fatty acids.
- 3. A method according to any of the preceding claims
 wherein the enzyme is a lipase enzyme.
 - 4. A method according to any of the preceding claims wherein the enzyme is immobilised on a support.
- 20 5. A method according to any of the preceding claims wherein the fat or oil of animal or vegetable origin contains a fatty acid triglyceride.
- 6. A method according to any of the preceding claims
 wherein the source of the fatty acid is kombo nut oil,
 coriander oil, sunflower oil, safflower oil,
 pomegranate seed oil, Manketti nut oil, fish oil,
 borage oil, pine nut oil or Impatiens balsamina seed
 oil or calendula seed oil.

30

... - ...

10


- 7. A fat or oil of animal or vegetable origin containing a retinyl ester of fatty acids contained in the fat or oil.
- 5 8. A retinyl ester of a fatty acid prepared according to the method of any of claims 1 to 6.
 - 9. A topical composition for application to human skin containing a retinyl ester prepared according to any of claims 1 to 6 or according to Claims 7 or 8.
 - 10. A conjugated or nonconjugated C18:3 and/or C18:4 retinol fatty acid ester.
- 15 11. A cosmetic method of treating human skin comprising applying thereto a topical composition according to claim 7.
- 12. A method of providing at least one skin care benefit

 20 selected from: treating/preventing wrinkling, sagging,
 aged and/or photodamaged skin; boasting collagen
 deposition on skin, boosting decorin production in
 skin; soothing irritated, red and/or sensitive skin;
 improving skin texture, smoothness and/or firmness;
 providing anti-inflammatory benefits; enhancing skin
 differentiation; reducing sebum production; or the
 prevention or treatment of acne



ABSTRACT

A method of producing a retinyl ester compound comprising subjecting a composition comprising retinyl or a retinyl sester and a fat or oil of animal or vegetable origins to enzyme catalysed trans-esterification in solvent free conditions to produce a retinyl ester.





This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
I LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER.

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.